What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study

Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Taj, Hafiza Munazza, Talib, Maryam, Siddiqa, Sania, Sarfraz, Azza, Sarfraz, Zouina, Robles-Velasco, Karla, Cherrez-Ojeda, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690388/
https://www.ncbi.nlm.nih.gov/pubmed/36360540
http://dx.doi.org/10.3390/healthcare10112199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690388/
https://www.ncbi.nlm.nih.gov/pubmed/36360540
http://dx.doi.org/10.3390/healthcare10112199

Ejemplares similares